Research we are currently funding:
Dr Wilmott and his team are focused on finding treatments for the more than 40% of patients that are not cured with our best current therapies.
This project is focused on overcoming the problem of relapse of melanoma in patients being treated by immunotherapy with checkpoint inhibitors.
The aim of this project is to discover which melanoma patients will benefit the most from the use of BET inhibitor drug treatment.
This project aims to find out how certain immune cells could be controlled and how they might be used to predict who will respond to immunotherapy.
The project has strong potential to achieve major benefits for patient care, because it brings the concept of personalised medicine much closer to reality.
This project will investigate how to hijack the stress-response techniques melanoma cells have developed to promote their survival.
This research will explore ways to help the immune system find and destroy melanoma cells.
The spread of melanoma to the groin lymph nodes is common but opinions are polarised about the best surgical approach.
Prof Zhang's team is studying a protein found in abnormal levels in melanoma. They've proved the protein helps cancer cells survive and resist treatment.
Impact we've achieved with our research:
Professor Xu Dong Zhang and his team investigated the role a particular protein plays in melanoma cell survival.
Researchers at Cancer Council NSW found that compared to the general population, men who survived melanoma have a higher risk of being diagnosed with prostate cancer later in life.
A research team led by Associate Professor Scott Byrne has discovered a vital mechanism that shows how cells in the immune system are hijacked by UV exposure.
Professor Xu Dong Zhang found the loss of a certain protein could cause melanoma to spread. When the team restored this protein back to normal levels, melanoma growth was stopped.